2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
3
Multiple Myeloma
2
Amyloidosis
2
Paraproteinemias
1
Monoclonal Gammopathy of Undetermined Significance
1
Amyloid Neuropathies, Familial
1
Interventions
Dexamethasone
12
Bortezomib
9
Lenalidomide
7
Cyclophosphamide
5
isatuximab
3
fludarabine
3
daratumumab
3
Granulocyte Colony-Stimulating Factor
3
pomalidomide
2
filanesib
2
dacetuzumab
2
Tacrolimus
2
Steroids
2
Injections, Subcutaneous
2
Filgrastim
2
Clinical Protocols
2
Calcium Dobesilate
2
Alemtuzumab
2
plerixafor
1
ofatumumab
1
nirogacestat
1
fludarabine phosphate
1
ficlatuzumab
1
epratuzumab
1
birtamimab
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Vorinostat
1
Tissue Banks
1
Thalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraproteinemias
×
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
×
Clear all
NCT07624760
2026-06-03
MGUS-PET
University of Zurich
Phase NA
Not yet recruiting
50 enrolled